We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
-1.43%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$115M
AUM Growth
-$8.8M
Cap. Flow
+$226K
Cap. Flow %
0.2%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
2
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$8.65M
2
LYEL icon
Lyell Immunopharma
LYEL
+$1.08M

Top Sells

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$9.4M
2
ARTV
Artiva Biotherapeutics
ARTV
+$105K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.39B
$75.5M 65.78%
4,289,304
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.04B
$15.5M 13.47%
489,194
– –
ALMS
3
Alumis Inc
ALMS
$3.57B
$13.9M 12.08%
4,619,803
+1,832,405
+66% +$8.65M
LYEL icon
4
Lyell Immunopharma
LYEL
$309M
$4.19M 3.65%
473,479
+118,369
+33% +$1.08M
ALXO icon
5
ALX Oncology
ALXO
$273M
$4.03M 3.51%
9,699,925
– –
ARTV
6
Artiva Biotherapeutics
ARTV
$487M
$1.73M 1.51%
1,148,975
-50,000
-4% -$105K
SLRN
7
DELISTED
ACELYRIN
SLRN
– –
-3,806,410
Closed -$9.4M

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q2 2025 Portfolio in Review

As of Q2 2025, venBio Partners held 7 positions worth $115M, down 7.1% from $124M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners's Q2 2025 filing shows 2 increased, 1 reduced and 1 closed positions. The largest sale was ACELYRIN, an estimated $9.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners added most to Alumis Inc in Q2 2025, an estimated $8.65M increase.
  • venBio Partners's biggest Q2 2025 reduction was Artiva Biotherapeutics, cutting an estimated $105K.
  • venBio Partners fully exited ACELYRIN in Q2 2025, selling an estimated $9.4M.
  • venBio Partners's ten largest holdings make up 100% of its $115M portfolio in Q2 2025.
  • venBio Partners opened 0 new positions and closed 1 in Q2 2025.
  • venBio Partners's portfolio value fell 7.1% quarter-over-quarter to $115M.

Based on venBio Partners's 13F filing for Q2 2025, filed 14 Aug 2025.